13. A compound which is 2-methyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy] pyrimidin-4-amine, or a pharmaceutically acceptable salt thereof.

14. A compound which is 2-Methyl-6-{[(1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}-N-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine, or a pharmaceutically acceptable salt thereof.

15. A compound which is S,S-N -[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-2-methyl-6-[(2-quinolin-2-ylcyclopropyl)methoxy]pyrimidin-4-amine, or a pharmaceutically acceptable salt thereof.

16. A compound which is S,S-2-methyl-N-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-{[2-(1,5-naphthyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-amine, or a pharmaceutically acceptable salt thereof.

17. A compound which is S,S-6-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-N-4-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof.

18. A compound which is 2-ethyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-6-[(2-pyridin-2-ylcyclopropyl)methoxy] pyrimidin-4-amine or a pharmaceutically acceptable salt thereof.

19. A compound which is 5-fluoro-6-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-N-4-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidine-2,4-diamine or a pharmaceutically acceptable salt thereof.

20. A compound which is 6-{[2-(3,3'-bipyridin-6-yl)cyclopropyl]methoxy}-2-methyl-N-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine or a pharmaceutically acceptable salt thereof.

21. A compound which is 6-{[2-(5-cyclopropylpyridin-2-yl)cyclopropyl]methoxy}-2-methyl-N-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine or a pharmaceutically acceptable salt thereof.

22. A compound which is 2-methyl-N-((5-methylisoxazol-3-yl)methyl)-6-((2-(pyridin-2-yl)cyclopropyl)methoxy)-pyrimidin-4-amine or a pharmaceutically acceptable salt thereof.

23. A compound which is 2-amino-4-{[(1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}-6-{[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]amino}pyrimidine-5-carbonitrile or a pharmaceutically acceptable salt thereof.

~~13~~24. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a compound of any one of the preceding claims ~~Claim 1~~ or a pharmaceutically acceptable salt thereof.

~~14~~25. A compound of any one of ~~C~~claims 1 to 23 or a pharmaceutically acceptable salt thereof for use in medicine.

~~15~~26. Use of a compound of any one of ~~C~~claims 1 to 23, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disorder selected from psychotic disorders, delusional disorders and drug induced psychosis; anxiety disorders, movement disorders, mood disorders, ~~and~~ neurodegenerative disorders and schizophrenia.

~~16~~27. A compound of any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof for use in ~~method for~~ treating a neurological or psychiatric disorder associated with PDE10 dysfunction in a mammalian patient ~~in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof~~.

~~17~~28. A compound of any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof for use in ~~method for~~ treating a neurological or psychiatric disorder associated with

striatal hypofunction or basal ganglia dysfunction in a mammalian patient ~~in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof~~.

~~18~~29. A compound of any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof for use in ~~method for~~ treating schizophrenia in a mammalian patient ~~in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof~~.